(Q40333043)

English

Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma

scientific article published on 23 February 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma (English)

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Debra M Sarasohn

object named as

Debra Sarasohn

9

0 references

Andrew D Zelenetz

object named as

Andrew D Zelenetz

16

0 references

object named as

Paul Hamlin

3

0 references

11

object named as

Alexia Iasonos

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Owen A O'Connor

17

object named as

Owen A O'Connor

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

author name string

John Gerecitano

1

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Carol Portlock

2

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Craig H Moskowitz

4

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

David Straus

6

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Philip Schulman

7

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Otilia Dumitrescu

8

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Jennifer Pappanicholaou

10

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Zhigang Zhang

12

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Qianxing Mo

13

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Endri Horanlli

14

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Celeste N Rojas

15

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

language of work or name

0 references

publication date

23 February 2011

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

17

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

8

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

2493-2501

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

Peripheral neuropathy: pathogenic mechanisms and alternative therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

A practical update on the use of bortezomib in the management of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

15 June 2018

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

17 June 2018

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

20 August 2018

Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

20 August 2018

Improved survival of follicular lymphoma patients in the United States.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5639472

20 August 2018

Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center

1 reference

https://pubmed.ncbi.nlm.nih.gov/21346146

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-10-1498

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40333043&oldid=1895531331"